<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325088</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0469</org_study_id>
    <nct_id>NCT03325088</nct_id>
  </id_info>
  <brief_title>Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient</brief_title>
  <acronym>NaRacAS</acronym>
  <official_title>Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>L'institut du thorax - INSERM UMR 1087 / CNRS UMR6291 - IRS-Université de Nantes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRSR-PL : Institut de Recherche en Santé Respiratoire des Pays de La Loire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a chronic inflammatory respiratory disease affecting 6 to 7% of the French adult&#xD;
      population and responsible of 1000 deaths in France every year. Many anti-inflammatory&#xD;
      treatments are available but few had been developed to target&#xD;
      hyperresponsiveness.Investigators and searchers of the Institut du thorax have recently&#xD;
      demonstrated the main involvement of Rac1 monomeric G protein in the contraction of airway&#xD;
      smooth muscle cells. They show that Rac1 is expressed in the airway smooth muscle cells in&#xD;
      mice and its activity is increased in the bronchi of asthma induced mice sensitized to&#xD;
      House-Dust Mite. They further demonstrate that Rac1 inhibition in mice by nebulisation&#xD;
      reduces airway hyperresponsiveness and pulmonary inflammation. Investigators and searchers of&#xD;
      the Institut du thorax would like to seek whether targeting Rac1 would be interesting in&#xD;
      asthmatic patients. Primary objective of this study is to determine if Rac1 expression and&#xD;
      activity in airway smooth muscle cells are increased in asthmatic patients compare to&#xD;
      controlled samples (deceased donor samples). Secondary objective is to determine whether&#xD;
      there is a correlation between Rac1 activity and asthma severity.&#xD;
&#xD;
      If Rac1 activity in airway smooth muscles is indeed increased in asthmatic patients depending&#xD;
      on asthma severity, Rac1 could be a potential target to treat airway hyperresponsiveness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be openly labeled in one of the following group&#xD;
&#xD;
        -  15 patients with severe asthma, without oral corticosteroids treatment.,&#xD;
&#xD;
        -  6 patients with mild to moderate asthma without treatment,&#xD;
&#xD;
        -  21 controlled samples from smooth muscle cells of non-asthmatic deceased donor Bronchial&#xD;
           endoscopy with bronchial biopsies will be assessed in all asthmatic patients, Control&#xD;
           samples will be obtained from tracheobronchial rings of cadaveric donor. Expression and&#xD;
           activity of Rac1 in airway smooth muscle will be determined by immuno-staining on&#xD;
           paraffinised biopsies.&#xD;
&#xD;
      Patients will undergo two study visits (D0: inclusion visit, D15: exploratory visit) and one&#xD;
      phone call at D21.&#xD;
&#xD;
      Inclusion Visit (D0):&#xD;
&#xD;
        -  Signature of the Informed consent,&#xD;
&#xD;
        -  Medical History,&#xD;
&#xD;
        -  Clinical examination,&#xD;
&#xD;
        -  Pulmonary Function Test,&#xD;
&#xD;
        -  Blood samples for fibroscopy safety,&#xD;
&#xD;
        -  ACT (Asthma Control Test), ACQ (Asthma Control Questionnaire), AQLQ (Asthma Quality of&#xD;
           Life Questionnaire), Morisky questionnaire&#xD;
&#xD;
      Exploratory visit (D15)&#xD;
&#xD;
        -  Clinical examination,&#xD;
&#xD;
        -  Bronchial endoscopy with biopsies Adverse event&#xD;
&#xD;
      Phone Call (D21)&#xD;
&#xD;
      - Adverse event&#xD;
&#xD;
      Recruitment will last 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity level and expression of Rac1 protein in airway smooth muscle cells of asthmatics vs non asthmatics samples</measure>
    <time_frame>at day 15</time_frame>
    <description>Mean of fluorescence intensity of Rac1-GTP and Rac1 in paraffinised biopsies of airway smooth muscle cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing any difference between activity level and expression of Rac1 in airway smooth muscle cells of severe versus non severe asthmatic patients.</measure>
    <time_frame>at day 15</time_frame>
    <description>Mean of fluorescence intensity of Rac1-GTP and Rac1 in paraffinised biopsies of airway smooth muscle cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing any correlation between Rac1-GTP/Rac1 ratio signal, pulmonary function tests and clinical data</measure>
    <time_frame>at day 15</time_frame>
    <description>Mean of fluorescence intensity of Rac1-GTP and Rac1 in paraffinised biopsies of airway smooth muscle cells.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Severe Asthma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild to moderate Asthma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients affected with untreated mild to moderate asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled Sample</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchial endoscopy</intervention_name>
    <description>Bronchial endoscopy will be performed after clinical examination and pulmonary function tests</description>
    <arm_group_label>Severe Asthma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchial biopsies</intervention_name>
    <description>5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies</description>
    <arm_group_label>Controlled Sample</arm_group_label>
    <arm_group_label>Mild to moderate Asthma</arm_group_label>
    <arm_group_label>Severe Asthma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchial alveolar enema</intervention_name>
    <description>For participants who had signed ancillary research consent</description>
    <arm_group_label>Mild to moderate Asthma</arm_group_label>
    <arm_group_label>Severe Asthma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Asthmatic Patient :&#xD;
&#xD;
               -  Male or Female from 18 to 70 years old,&#xD;
&#xD;
               -  Diagnosis of asthma confirmed by&#xD;
&#xD;
                    -  Existence of one or more following symptoms over 3 months at least (wheezing&#xD;
                       dyspnea, wheezing, chronic cough and tightness in the chest…)&#xD;
&#xD;
                    -  AND past pulmonary function test showing a reversible obstructive&#xD;
                       ventilatory syndrome after inhaled short-acting bronchodilators (improvement&#xD;
                       of FEV1 above 12% and at least 200 mL FEV1 gain compare to&#xD;
                       pre-bronchodilatator FEV1)&#xD;
&#xD;
                    -  AND a removal of the clinically suspected differential diagnoses of asthma&#xD;
                       (vocal cord dysfunction, Churg-Strauss syndrome etc…). The comorbidities&#xD;
                       should have been explored and treated or on treatment at enrollment.&#xD;
&#xD;
               -  Subject agreed to participate to the study and the biological samples collection,&#xD;
&#xD;
               -  Subject is affiliate to a social security system.&#xD;
&#xD;
          -  Inclusion criteria for severe asthmatic patient :&#xD;
&#xD;
        Patient with one of the following criterion will be considered as severe asthmatic patient&#xD;
        :&#xD;
&#xD;
          -  Patient with a controlled asthma but using high dose of inhaled corticosteroids with&#xD;
             another therapeutic classes,&#xD;
&#xD;
          -  OR Patient with uncontrolled asthma despite treatment,&#xD;
&#xD;
          -  OR Patient with worsening asthma despite treatment.&#xD;
&#xD;
             --&gt;Inclusion criteria for non-severe asthmatic patients :&#xD;
&#xD;
          -  Moderate Asthmatic patient without standard of care treatment since at least one week&#xD;
             before the exploratory visit.&#xD;
&#xD;
             --&gt;Controlled sample:&#xD;
&#xD;
          -  Non asthmatic cadaveric adults&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asthmatic Patient :&#xD;
&#xD;
               -  Underage,&#xD;
&#xD;
               -  Pregnant or breast-feeding women,&#xD;
&#xD;
               -  Adult on guardianship&#xD;
&#xD;
               -  Active smoker (smoked or Inhaled),&#xD;
&#xD;
               -  former smokers (smoked or Inhaled) with a smoking history of ≥10 pack years since&#xD;
                  less than 5 years.&#xD;
&#xD;
               -  Patient with asthma exacerbation the 4 past weeks before the exploratory visit..&#xD;
&#xD;
               -  Patient treated by long term oral corticosteroids or ongoing biological therapy&#xD;
                  or stopped within the 3 months before exploratory visit.&#xD;
&#xD;
               -  Patient with severe acute or chronic organ disorder (cardiovascular, respiratory,&#xD;
                  hepatic, renal, malabsorption)&#xD;
&#xD;
               -  Patient with history of unstable angina,&#xD;
&#xD;
               -  Patient with platelet count abnormality, or primary or acquired thrombopathy, or&#xD;
                  an aPTT (activated Partial Thromboplastin Time) greater than or equal to 1,5&#xD;
                  times normal or patient with a Quick Time &gt; 26 seconds&#xD;
&#xD;
               -  Patient under a systemic immunomodulatory or immunosuppressive treatment&#xD;
&#xD;
               -  Patient with anticoagulants or anti-platelet aggregating drugs other than D-lysin&#xD;
                  acetylsalicylate and that could not be suspended before the bronchial fibroscopy.&#xD;
&#xD;
               -  Patient with hypersensitivity to the treatment used during the bronchial&#xD;
                  fibroscopy: Hydroxyzine, Midazolam, Xylocaine.&#xD;
&#xD;
               -  Patient with AME (Government Medical Assistance),&#xD;
&#xD;
               -  Patient having physical and psychological disabilities to follow the protocol,&#xD;
&#xD;
               -  Patient included in another interventional research protocol,&#xD;
&#xD;
               -  Patient having risk factors of Creutzfeld-Jakob disease&#xD;
&#xD;
          -  Controlled sample:&#xD;
&#xD;
               -  Asthmatic patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François-Xavier BLANC, Pr</last_name>
    <phone>+33(0)240165533</phone>
    <email>xavier.blanc@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François-Xavier BLANC</last_name>
    <phone>+33(0)240165533</phone>
    <email>xavier.blanc@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Xavier BLANC</last_name>
      <phone>02.40.16.55.33</phone>
      <email>xavier.blanc@chu-nantes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Asthma</keyword>
  <keyword>airway smooth muscle cells</keyword>
  <keyword>Rac1 protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

